卖什么
RNA medicines for liver diseases
商业模式拆解
买家：谁掌握预算？
未核实Pharma R&D / business development heads (e.g. GSK AI/ML, Boehringer Ingelheim cardiometabolic research quoted as partners).
触发点：什么让他们现在购买？
Need for validated liver disease targets and human-derived datasets; 1.5m people die globally of liver disease with limited treatments.
工作流：什么输入变成什么输出？
AI over proprietary gene perturbation atlases and patient disease atlases to predict targets, validated in human models (perfused livers, diseased tissue slices, primary cells), then in-house RNA therapy making; pipeline led by development candidate OB-220 for significant fibrosis.
经济账：省了什么，怎么收费？
Two routes: internal RNA pipeline and partnerships; a quoted commentator says the GSK deals show disease-specific datasets are valued like discovery IP. Deal terms not disclosed.
渠道：怎么接触到客户？
Partnership deals with large pharma (GSK research completed Nov 2025 per news page); no self-serve.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2020 冬季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.